Majd Al Assaad

EXaCT-2: An augmented and customizable oncology-focused whole exome sequencing platform

EXaCT-2 is a whole exome sequencing platform that detects various cancer-related genomic features with high accuracy and sensitivity, outperforming standard assays in detecting sub-clonal mutations and molecular metrics.

Paired plus-minus sequencing is an ultra-high throughput and accurate method for dual strand sequencing of DNA molecules

This paper introduces ppmSeq, a sequencing technology that improves accuracy and efficiency in detecting SNVs by sequencing both DNA strands, showing superior performance in clinical applications like ctDNA detection.

Genomic alterations in the YAP/TAZ pathway are associated with stem cell-like castration-resistant prostate cancer

The paper identifies genomic alterations in the YAP/TAZ pathway associated with stem cell-like castration-resistant prostate cancer using transcriptomic and whole-genome sequencing data.

Pan-Cancer PDOs Preserve Tumor Heterogeneity and Uncover Therapeutic Vulnerabilities

This study develops a pan-cancer PDO platform to preserve tumor heterogeneity and identify therapeutic vulnerabilities, finding that 58% of PDOs respond to Talazoparib and combination screens reveal resistance-overcoming drugs.

Whole Genome Landscape Analysis of Homologous Recombination Deficiency in a Pan-Cancer Cohort

The paper analyzes whole-genome sequencing data from a pan-cancer cohort to define HRD, showing it extends beyond BRCA1/2 mutations and highlights the benefits of WGS over commercial assays for HRD detection.

Weakly-Supervised Tumor Purity Prediction FromFrozen H&E Stained Slides

This paper introduces a weakly-supervised method to predict tumor purity from H&E stained slides, achieving high accuracy and enabling clinical applications.